What is the recommended IGF-1 DES dosage?

IGF-1 DES dosing varies by experience level. Beginners typically start at 50mcg daily, moderate users at 80mcg daily, and aggressive protocols use 120mcg daily.

How do you reconstitute IGF-1 DES?

IGF-1 DES typically comes in 0.1mg or 1mg vials. Add 1mL of bacteriostatic water to the vial. Use our free calculator for exact syringe units based on your desired dose.

What is the half-life of IGF-1 DES?

The half-life of IGF-1 DES is ~20-30 minutes. This determines how frequently you need to dose for consistent blood levels.

IGF-1 DES

Growth HormoneInjectionResearchGrade C~20-30 minutes half-life

IGF-1 AnalogSite-Specific GrowthMuscle HyperplasiaGrowth FactorAnabolic4 weeks on / 4 weeks off

Benefits

Site-specific muscle growth when injected locally post-workout

Approximately 10x more potent than native IGF-1

Promotes muscle hyperplasia (new muscle fiber creation)

Short half-life limits prolonged systemic exposure

Stimulates satellite cell proliferation and differentiation

Supports localized tissue repair and recovery

Half-Life

~20-30 minutes

Route

Injection

Frequency

Daily

Vial Sizes

0.1mg, 1mg

BAC Water

1mL

Safety Grade

Grade C

Open IGF-1 DES Dosage Calculator

Calculate exact syringe units for your vial and dose

About IGF-1 DES

IGF-1 DES (des(1-3) Insulin-like Growth Factor-1) is a 67-amino acid truncated analog of IGF-1, missing the first three N-terminal amino acids (Gly-Pro-Glu). This structural modification eliminates binding to all six IGF binding proteins (IGFBPs), meaning the entire dose remains bioactive in free form. The result is roughly 10-fold greater potency than native IGF-1, but with a half-life of only 20-30 minutes. This rapid clearance makes IGF-1 DES uniquely suited for localized intramuscular injection, allowing site-specific muscle hypertrophy and hyperplasia without prolonged systemic IGF-1 elevation. It activates the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt/mTOR and MAPK/ERK signaling to drive protein synthesis, satellite cell proliferation, and new muscle fiber formation.

Who Should Consider IGF-1 DES

Experienced peptide users seeking localized muscle growth in lagging body parts
Advanced athletes with prior IGF-1 or growth hormone experience
Individuals researching site-specific anabolic signaling and muscle hyperplasia
Adults recovering from localized muscle injuries (under medical supervision)
Researchers studying IGF-1R activation independent of IGFBP modulation

How IGF-1 DES Works

IGF-1 DES binds and activates the IGF-1 receptor (IGF-1R) with equal affinity to native IGF-1 but without sequestration by IGF binding proteins. The deletion of the N-terminal tripeptide Gly-Pro-Glu removes the primary IGFBP recognition site, allowing 100% of the administered dose to remain in free, bioactive form. Upon receptor binding, IGF-1R undergoes autophosphorylation and recruits IRS-1 (insulin receptor substrate-1), activating two principal signaling cascades. The PI3K/Akt/mTOR pathway drives protein synthesis through phosphorylation of p70S6K and 4E-BP1, directly increasing translation of muscle-specific mRNAs. Simultaneously, the MAPK/ERK pathway promotes satellite cell proliferation — the mechanism behind muscle hyperplasia rather than just hypertrophy. Because IGFBPs normally sequester 95-98% of circulating IGF-1, the DES variant bypasses this buffer entirely, producing a potent but transient anabolic signal at the injection site. The short half-life (~20-30 minutes) means that local tissue exposure is high while systemic levels return to baseline quickly, reducing off-target growth stimulation in organs and other tissues.

What to Expect

Days 1-3

Initial blood glucose fluctuations may occur. Mild pump sensation in injected muscles reported within the first session. Injection site soreness or redness possible. Establish post-workout timing and blood sugar management routine.

Weeks 1-2

Increased muscle fullness and pumps in injected muscle groups during and after training. Temporary water retention around injection sites. Appetite changes and mild hypoglycemia episodes if carb intake is not managed.

Weeks 3-4

Measurable improvements in injected muscle group size and recovery speed. Localized growth effects become visible in trained and injected areas. Peak response window for satellite cell activation and new fiber formation.

Weeks 5-6

extended cycle

Continued but potentially diminishing returns as IGF-1R sensitivity decreases. Cycle off after 4-6 weeks. Gains in muscle density and localized size should be retained with consistent training through the off period.

Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	50mcg	Daily
Moderate	80mcg	Daily
Aggressive	120mcg	Daily

Note: Truncated IGF-1 analog missing first 3 amino acids (des(1-3)IGF-1). Does not bind IGF binding proteins, giving it ~10x greater potency than native IGF-1 but a very short half-life. Inject intramuscularly into the target muscle immediately post-workout for site-specific growth. Use insulin syringes for accurate dosing. Monitor blood sugar closely.

How to Inject IGF-1 DES

Inject intramuscularly into the target muscle group immediately after training (within 15 minutes post-workout). Use a 29-31 gauge insulin syringe. Split bilateral doses between left and right sides of the muscle group being trained. Rotate between muscle groups based on training split. Consume fast-acting carbohydrates within 15 minutes of injection to counter potential hypoglycemia. Do not inject into the same muscle site more than 2-3 times per week.

Cycling Protocol

On Period

4 weeks

Off Period

4 weeks

Short cycles of 4-6 weeks are standard due to potential IGF-1R desensitization with prolonged use. Some protocols use only on training days (3-5 days per week) to extend cycle duration while minimizing total exposure. Allow a full 4-week off period between cycles to restore receptor sensitivity.

Pharmacokinetics

Half-Life

25min

Bioavailability

IM: ~100% bioactive (no IGFBP sequestration); SC: ~100% absorption but slower onset

Tmax

5-10 minutes (IM injection)

Data Confidence

moderate

Source: Estimated 20-30 min based on near-zero IGFBP affinity vs native IGF-1 (bound t½ ~12-15h, free t½ ~10 min); Francis et al. 1988 PMID 2454805, Ballard et al. 1996 PMID 8930132

Pharmacokinetics — Active Dose Over Time

Loading the interactive decay curve.

Side Effects

Hypoglycemia (low blood sugar) — always have fast-acting carbs available. Injection site redness, swelling, or irritation. Mild headaches. Water retention and joint discomfort at higher doses. Potential for localized tissue overgrowth with chronic use at the same site.

Contraindications

Active or history of any malignancy — IGF-1R activation may accelerate tumor cell proliferation
Pregnancy or breastfeeding — no safety data available; stimulates cell growth pathways
Type 1 diabetes or poorly controlled type 2 diabetes — high risk of severe hypoglycemia
Individuals under 18 or with open growth plates — may cause disproportionate skeletal growth
Known hypersensitivity to IGF-1 or related growth factor peptides
Active acromegaly or elevated baseline IGF-1 levels
Diabetic retinopathy — IGF-1 may worsen retinal neovascularization

Drug Interactions

Insulin — significantly increased hypoglycemia risk; concurrent use requires intensive glucose monitoring and dose reduction
Sulfonylureas and other oral hypoglycemic agents — additive blood sugar lowering; monitor glucose closely
Growth hormone (HGH) — synergistic IGF-1 axis stimulation; amplifies both anabolic effects and side effects including water retention and glucose dysregulation
IGF-1 LR3 — combining short-acting and long-acting IGF-1 analogs may cause excessive receptor stimulation and prolonged hypoglycemia
GLP-1 receptor agonists (semaglutide, tirzepatide) — both affect glucose homeostasis; increased hypoglycemia risk
Corticosteroids — may blunt IGF-1 anabolic effects through catabolic opposition and impaired protein synthesis